Press release
Oral Biologics And Biosimilars Market 2020 Global Analysis, Trends, Forecast up to 2030 | Merck & Co, GlaxoSmithKline, Novo Nordisk, ALK-Abello A/S, Aimmune Therapeutics, Inc.
Oral Biologics And Biosimilars Market
The global oral biologics and biosimilars market reached a value of nearly $3,076.1 million in 2019, having grown at a compound annual growth rate (CAGR) of 6.5% since 2015, and is expected to grow at a CAGR of 17.1% to nearly $5,787.9 million by 2023. Also, the market is expected to growth to $8,687.7 million in 2025 at a CAGR of 22.5% and to $23,585.5 million in 2030 at a CAGR of 22.1%.
The key drivers of the oral biologics & biosimilars market include:
Technological Advances:
Technology is expected to be a continued driver of market growth during this period. An area of particular development is likely to be physiology simulation modeling. Markets such as this one will benefit from the greater efficiencies offered by developments in this area. For example, Eli Lilly and Pfizer have adopted Amazon’s Elastic Compute Cloud (EC2) platform to conduct simulation models in early drug discovery that have been operational within hours, whereas traditional models would have taken weeks to conduct simulations. The Open Innovation Drug Discovery program is another initiative by Lilly to enhance the research and development of biologics.
Browse Complete Report @ https://www.thebusinessresearchcompany.com/report/oral-biologics-and-biosimilars-market
Oral Biologics & Biosimilars Market Segmentation:
The oral biologics & biosimilars market is segmented by therapeutic mechanism, disease, molecule type, distribution channel and by geography.?
By Therapeutic Mechanism - The oral biologics & biosimilars market can be segmented by therapeutic mechanism
a. Tumor Necrosis Factor-Alpha Inhibitors
b. Lymphocyte Modulators
c. Interleukin Inhibitors
d. GPCR (insulin, growth hormone, parathyroid hormone) Modulators
e. Immunostimulants
f. Others
The others (Interferons, Opioid receptors, Calcitonin receptor) was the largest segment of the oral biologics and biosimilars market by therapeutic mechanism, accounting for $676.1 million of the total market in 2019.
By Disease – The oral biologics & biosimilars market can be segmented by disease
a. Diabetes
b. Arthritis & Chron`s Disease
c. Cancer
d. Infectious Diseases
e. Other Autoimmune Diseases
f. Others Diseases
The infectious diseases was the largest segment of the oral biologics and biosimilars market by disease, accounting for $2,305.6 million or 74.9% of the total market in 2019 and this market is expected to grow at a CAGR of 7.1% during 2019-2023. The diabetes market is expected to be the fastest-growing segment going forward at a CAGR of 82.6%.
Request For A Sample Copy Of This Report @ https://www.thebusinessresearchcompany.com/sample.aspx?id=3361&type=smp
By Geography - The oral biologics & biosimilars market is segmented into
1.North America
2.Western Europe
3.Asia Pacific
4.Eastern Europe
5.South America
6.Middle East
7.Africa
Some of the major key players involved in oral biologics & biosimilars market are
• Merck & Co
• GlaxoSmithKline
• Novo Nordisk
• ALK-Abello A/S
• Aimmune Therapeutics, Inc.
Place a DIRECT PURCHASE ORDER of entire 300+ pages report @ https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=3361
Contact Information:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 8897263534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow us on Blog: http://blog.tbrc.info/
About US:
The Business Research Company has published over 1000 industry reports, covering over 2500 market segments and 60 geographies. The reports draw on 150,000 datasets, extensive secondary research, and exclusive insights from interviews with industry leaders. The reports are updated with a detailed analysis of the impact of COVID-19 on various markets after WHO declared COVID-19 as a pandemic.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Oral Biologics And Biosimilars Market 2020 Global Analysis, Trends, Forecast up to 2030 | Merck & Co, GlaxoSmithKline, Novo Nordisk, ALK-Abello A/S, Aimmune Therapeutics, Inc. here
News-ID: 2128907 • Views: …
More Releases from The Business research company
Segment Evaluation and Major Growth Areas in the Personalized Testing and Supple …
The personalized testing and supplements sector is gaining remarkable traction, driven by advancements in technology and a rising consumer focus on tailored health solutions. As more individuals seek customized wellness options, this market is set to experience substantial expansion in the coming years. Here's an in-depth look at its current valuation, key players, significant trends, and the main market segments shaping its future.
Market Valuation and Expansion Forecast for Personalized Testing…
Top Players and Market Competition in the Skin Microbiome Industry
The skin microbiome market is emerging as a significant area of interest due to growing awareness about the critical role of skin health and innovative skincare technologies. As research advances and consumer preferences shift towards more natural and science-backed products, this market is set to undergo substantial growth. Let's explore the current market size, key players, driving factors, and upcoming trends shaping the skin microbiome industry.
Projected Expansion in the Skin…
Key Strategic Developments and Emerging Changes Shaping the Upadacitinib Market …
The upadacitinib market is poised for significant expansion over the coming years, driven by advances in treatment options and increasing awareness of autoimmune diseases. This report delves into the market's current size, key drivers, major players, and the emerging trends shaping its future trajectory.
Steady Growth Expected in Upadacitinib Market Size Through 2029
The market for upadacitinib is projected to reach $2.54 billion by 2029, growing at a robust compound annual…
Analysis of Key Market Segments Driving the Alzheimer's Disease Diagnostic Marke …
The Alzheimer's disease diagnostic sector is rapidly evolving as advancements in technology and healthcare infrastructure open new possibilities for early detection and personalized treatment. With rising awareness and innovative approaches, this market is poised for significant growth in the coming years. Let's explore the current market size, key drivers, leading companies, and emerging trends that are shaping this critical healthcare field.
Projected Market Size and Growth Trends in Alzheimer's Disease Diagnostics…
More Releases for Disease
Protheragen Announces Disease Model Development Services to Enhance Rare Disease …
Protheragen announced the release of its disease model development services provided to enhance rare disease research. With an increasing focus on rare diseases and the need for tailored research models, Protheragen is dedicated to providing cutting-edge solutions to support this important area of medical research.
Rare diseases, which affect a small percentage of the population, pose unique challenges for researchers due to their limited understanding and lack of available treatment options.…
Biopharmaceutical Fermentation Market 2022 | Growing Morbidity of Genetic Diseas …
According to Precision Business Insights (PBI), the latest report, the biopharmaceutical fermentation market is expected to be valued at USD 10,302.1 million in 2022, growing at a 4.7% CAGR from 2022 to 2028. The growing prevalence of chronic illness, cancer, cardiac diseases, infectious diseases, antibiotic resistance, autoimmune diseases, etc., globally causes the leaning toward biopharmaceutical products, which show promising results in the research studies. Moreover, new findings by the…
Global Inflammatory Bowel Disease (IBD) Market Key Players Analysis, Disease Ind …
Global Inflammatory Bowel Disease (IBD) Market, valued at USD 210.5 Billion in the year 2020 has been driven by factors such as the increasing prevalence of Ulcerative Colitis and Crohn’s Disease, advances in medical technology, government support for inflammatory bowel disease treatment research, and the ubiquity of anxiety and depression. Moreover, factors such as the irregular food habits, unhealthy lifestyle of people, increased level of pollution and increase in alcohol…
Moyamoya Disease Market - A Scientometric Assessment of Disease During 2018-23
Market Highlight:
Moyamoya disease (MMD) is a chronic, cerebrovascular disease characterized by progressive stenosis in the internal carotid artery and an abnormal vascular network at the base of the brain. The stroke is one of the significant symptoms of moyamoya disease, which further leads to paralysis of the face, arms, and legs, loss of speech, and temporary loss of neurologic function of body parts, visual disturbances, headaches, developmental delay, and…
Refsum Disease Industry An Overview of A New Disease - 2018
"Refsum Disease" is a genetic disorder which is inherited as an autosomal recessive trait. The condition is characterized by progressive loss of vision (retinitis pigmentosa), failure of muscle coordination (ataxia), degenerative nerve disease (peripheral neuropathy), and dry, rough, scaly skin (ichthyosis). The accumulation of fatty acid (phytanic acid) in blood plasma and tissues is the main cause of refsum disease. This occurs due to malfunction of the enzyme producing gene…
Chagas Disease (Infectious Disease) Pipeline Forecast Report, H1, 2017 [MRH]
Market Research Hub's Pharmaceutical and Healthcare latest pipeline guide Chagas Disease - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Chagas Disease Market (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and…
